COSCIENS Biopharma Inc (CSCI) 銘柄情報

Completely lack of ability in doing clinical trials. Don’t trust these management!

Damn it..bad management! A crab!

Great, now another reverse split coming. Now my .5 shares at $25,000/share will become .1 shares at $125,000/share.... lol but hey, I'll get .1 warrant to help cover my losses.... lol

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Russian Sub runs aground in America

ok this is my last one

SHATNERS early days (ca. 1963 ) in show bizz

AEZZZZZZZZZZZZZZZZZZZZZZZZZS SUCKS

ZZZZZZZZZZZZZZZZZZZZZZ....................................................................................................................................................NO BODY SELLING EITHER......................................................................................

or head north to escape the heat

strike it rich like the Bev, Hillbullies

MIGHT BE ON THIS LIST SOON

https://www.sec.gov/divisions/enforce/delinquent/delinqindex.htm

think this one is done..... ?????

were they trying to eliminate COVID -9.or what did Toronto think they are a foreign issuer...duhh

exactly,i have no idea what we were thinking,live and learn bro,God bless and good luck

Nearly all management had been in this company for many many years.. seems dead wood already .. milking this company!

This company has been listed for more than 30 years! But nothing achieved, really!

me too bro,God bless and good luck

I should have known this is crab as there is No financial institution holding! This management has milk from shareholders for 30+ years !

sorry bro,put this pos behind u like i did,maybe it will jump a little on pedi approval but who knows how long that will take,only chance for this is other uses for macrilen but at the pace klauss and aezs goes that will take a decade,we should have known by aezs past,i was up 85k and ended up losing 15k so i feel your frustration,God bless and good luck

Wtf, E&Y declined the reappointment as auditors !!

they will try---- its not like a run on the stock.............

Shorters are bastard earning nothing in shorting this kind of stock!!

what a f disaster,God bless and good luck

Very bad… 99% holdings in hand of public!!!

Confuscios say ''buy low---- sell high''

Over 30 years company…Only 11 employees and very few financial institutional investors …very bad…

to boot klauss is making near 750k a yr for cratering aezs pps,sma aezs and klauss,God bless all

what a f disaster this has turned out to be,we all make mistakes and this is 1 for both of us,f aholes take forever to get things done,novo backed out of deal.this could easily go down below a buck again,sorry but we both fd up with this pos,tax rt off is all,and we all make mistakes sometimes,should have looked at past performance also,since its inception all it has done is go down,unless macrilen can be used for other things besides a test they got 0,sorry for our losses,God bless and good luck

A crook..

No more oral COVID pill… a spam..

this stock seems to ALWAYS come back in SPADES

a good friend of mine had 2 of those Citroens... a engineered marvel

1950's were the days of the Jackal's

Instead of giving updates, company chooses to publish those old information which already published .. it is not alert at all! It just so amazing a company keeps on publishing old information not bothering how public would expect.

getting alerts every day now on AEZS

on the list ???


Listing of Company Delinquent Filings Update
10/04/2022
You are subscribed to receive Listings of Company Delinquent Filings from the Securities and Exchange Commission.

This information has recently been updated and is now available.

https://www.sec.gov/divisions/enforce/delinquent/delinqindex.htm

BOND JAMES couldnt save it,,, but James BLOND will ,,,,,with secret tricks


watch

On November 16, 2020, the Company announced that it had entered into the Novo Amendment related to the development and commercialization of macimorelin. Novo is currently marketing macimorelin in the U.S. under the trade name Macrilen™ for the diagnosis of AGHD. Aeterna, in collaboration with Novo, is currently developing the expanded use of macimorelin for the diagnosis of CGHD, an area of significant unmet medical need.

On December 7, 2020, the Company entered into an exclusive licensing agreement with Consilient Health Limited (“CH” or “Consilient”) for the commercialization of macimorelin in the European Economic Area and the United Kingdom. In December 2021, the Department of Health and Social Care in the United Kingdom approved a list price which triggered a $226 (€0.2 million) pricing milestone payment from CH to the Company. In Germany, a list price was approved on June 15, 2022 which triggered a second $226 (€0.2 million) pricing milestone payment from CH to the Company. We shipped initial batches of macimorelin (Ghryvelin®) to Consilient in the first quarter of 2022. Consilient launched the product in the United Kingdom, Sweden and Denmark in May 2022 and launches in Germany and Finland are scheduled for July 2022.

We entered into license and supply agreements with NK Meditech Ltd. (“NK”), a subsidiary of PharmBio Korea, effective November 30, 2021, and a distribution and commercialization agreement with ER Kim Pharmaceuticals Bulgaria Food (“ER-Kim”), effective February 1, 2022. The agreements with NK are related to the development and commercialization of macimorelin for the diagnosis of AGHD and CGHD in the Republic of Korea, while the agreement with ER-Kim is related to the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries.

On April 19, 2022, we announced that European Patent Office had issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin (Ghryvelin®; Macrilen™) for use to diagnose GHD in adults.

Follow the money folks!!!

#ELGORDODAMUS
$AEZS

Could this become a $100 ticker
In the next 6-18 months
It’s been on my radar for over a year
Let see how it plays out.

#ELGORDODAMUS
$AEZS

yah, when you got a billion shares--there are lots of reverse splits to be done --- ..................................................................

AEZS wants to be a BLUE chip outfit

Further adjourning shareholders meeting. Klaus, don’t waste your time. It’s time to consider AEZS to buy back some share from the market. Or else AEZS is facing delisting..

Really pk..

Just a pump & dump.. really crab!

Damn…

patrick i have to be honest,i sold because i needed the money to fix driveway,took a big hit but didnt have a choice really,God bless and good luck,sorry we were wrong about this 1 ,i dont know whats going to happen with this,if catalysts come to fruition it will jump back but at the rate they are going it could take a while and rs are almost always bad,God bless and good luck bro

The share consolidation did not get shareholders approval… going to be delisted or going to pink… AEZS has sufficient cash to buy back 100 million shares and still leaving plenty amount for R&D. Buy back shares also show management is confident on its current candidates! AEZS is very risky facing delisted! What have you voted on this?

no way to test kids for ghd,no way,after approval it will help a lot,again no way to test kids for ghd,0 competition,what sucks is the delay because of putins war and the other catalysts takng forever like the covid pill,no urgency,sh feel it,check out tsoi,cant recommend per rules but check it out

Shorters keep shorting this stock in view of RS. Management is bad and this stock is crab!